Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases
Executive Summary
Teva's business appears to be stabilizing but the company needs to resolve outstanding opioid liability litigation. CEO Schultz said he is hopeful a national settlement framework will be finalized.
You may also be interested in...
J.P. Morgan Notebook Day 1: No Big Deals, But Plenty Of Pipeline, Commercial Highlights
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: There was no big M&A, but biopharma CEOs discussed deals they're pursuing. Also, Novartis's Zolgensma reimbursement insights, Sarepta's third DMD filing, Bristol's post-merger progress and more highlights.
J.P. Morgan Notebook Day 1: No Big Deals, But Plenty Of Pipeline, Commercial Highlights
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: There was no big M&A, but biopharma CEOs discussed deals they're pursuing. Also, Novartis's Zolgensma reimbursement insights, Sarepta's third DMD filing, Bristol's post-merger progress and more highlights.
Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks
With a US FDA endorsement, the drug – soon to join AbbVie’s portfolio under the companies’ $63bn merger – is the first oral option in its class and the first CGRP inhibitor approved to stop a migraine when it strikes.
Need a specific report? 1000+ reports available
Buy Reports
